A 54-year-old male who had received prior intravesical mitomycin (MMC) treatment.
She started treatment with intravesical gemcitabine, presenting within five minutes of the end of the third instillation, bladder spasm with spontaneous mimicry, profine tension sweating and negative feeling of dizziness (urcultiva grade 1).
The patient continued treatment until the seventh dose of gemcitabine, which presented a new episode of hypotension, subsequent hypotension/50 mmHg, and sweating (grade 2)5, negative voiding cystourethrogram).
It was decided to discontinue treatment after the second adverse event (AE).
